BioCentury
ARTICLE | Clinical News

CPX-351: Completed Phase II enrollment

June 15, 2015 7:00 AM UTC

Celator completed enrollment in an open-label, U.S. Phase II trial to evaluate IV CPX-351 in up to 2 induction cycles plus 4 consolidation courses in 26 patients with acute hematologic malignancies, i...